![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Elscint Holding Gamida-Cell, Teva to Develop Commercialize StemEx
Elscint Holding Gamida-Cell, Teva to Develop Commercialize StemEx
Elscint has announced that Teva Pharmaceutical has exercised its option to enter into a joint venture with Gamida-Cell, in which Elscint (through a wholly owned subsidiary) holds 29.2 percent on a fully diluted basis, in order to develop and commercialize StemEx for the treatment of leukemia and lymphoma.
Gamida-Cell is a leader in the expansion of hematopoietic (blood) stem-cell therapeutics in clinical development for cancer and autoimmune diseases, as well as future regenerative cell-based medicines including cardiac and pancreatic repair.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct